WO2024015760A3 - Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2) - Google Patents

Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2) Download PDF

Info

Publication number
WO2024015760A3
WO2024015760A3 PCT/US2023/069923 US2023069923W WO2024015760A3 WO 2024015760 A3 WO2024015760 A3 WO 2024015760A3 US 2023069923 W US2023069923 W US 2023069923W WO 2024015760 A3 WO2024015760 A3 WO 2024015760A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
omicron
variant
monoclonal antibodies
Prior art date
Application number
PCT/US2023/069923
Other languages
French (fr)
Other versions
WO2024015760A2 (en
Inventor
James E. Crowe, Jr.
Robert H. CARNAHAN
Naveenchandra SURYADEVARA
Pavlo Gilchuk
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of WO2024015760A2 publication Critical patent/WO2024015760A2/en
Publication of WO2024015760A3 publication Critical patent/WO2024015760A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.
PCT/US2023/069923 2022-07-13 2023-07-11 Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2) WO2024015760A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263388871P 2022-07-13 2022-07-13
US63/388,871 2022-07-13

Publications (2)

Publication Number Publication Date
WO2024015760A2 WO2024015760A2 (en) 2024-01-18
WO2024015760A3 true WO2024015760A3 (en) 2024-04-18

Family

ID=89537417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069923 WO2024015760A2 (en) 2022-07-13 2023-07-11 Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)

Country Status (1)

Country Link
WO (1) WO2024015760A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210277092A1 (en) * 2020-02-11 2021-09-09 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20210347860A1 (en) * 2020-05-11 2021-11-11 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
WO2022046888A1 (en) * 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
WO2022147290A1 (en) * 2020-12-31 2022-07-07 The Broad Institute, Inc. Cross-neutralizing sars-cov2 antibodies
US20220227844A1 (en) * 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210277092A1 (en) * 2020-02-11 2021-09-09 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20210347860A1 (en) * 2020-05-11 2021-11-11 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
WO2022046888A1 (en) * 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
WO2022147290A1 (en) * 2020-12-31 2022-07-07 The Broad Institute, Inc. Cross-neutralizing sars-cov2 antibodies
US20220227844A1 (en) * 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies

Also Published As

Publication number Publication date
WO2024015760A2 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
EP4356924A3 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A8 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
EA200801027A1 (en) ANTIBODIES AGAINST MYOSTATIN
EP2476704A3 (en) Humanized monoclonal antibodies to heptocyte growth factor
IL97909A (en) Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences
WO2020169755A3 (en) Antibodies
WO2022015573A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
WO2022170126A3 (en) Compounds specific to coronavirus s protein and uses thereof
EA200401081A1 (en) FAB FRAGMENTS OF THE MONOCLONAL HUMAN ANTIBODY, DIRECTED AGAINST GLYCOPROTEIN E2 HCV AND HAVING NEUTRALIZING ACTIVITY IN VITRO
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
MX2022007231A (en) Anti-mertk antibodies and methods of use thereof.
WO2020076789A3 (en) Combinations of anti-staphylococcus aureus antibodies
WO2024015760A3 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
WO2022204713A3 (en) Antibodies to sars-cov-2
WO2021231651A3 (en) Sars-cov2 neutralizing single domain antibody constructs
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
TN2020000157A1 (en) Binding molecule having neutralizing activity against middle east respiratory syndrome coronavirus
WO2023019174A3 (en) Antibodies to sars-cov-2
WO2022177990A3 (en) Modified sars-cov-2 spike polypeptides and nanoparticles thereof
WO2021257695A3 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
WO2022036049A3 (en) Antiviral stapled peptides against sars-cov-2
WO2022184942A3 (en) Biomarkers
WO2019156758A3 (en) Antibody-mediated neutralization of chikungunya virus
MX2022003762A (en) Binding molecule specific for lif and use thereof.
WO2023004431A3 (en) Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23840444

Country of ref document: EP

Kind code of ref document: A2